GLP-1s are powerful.

They reduce appetite.

They lower A1C.

They drive meaningful weight loss.

For many patients, they are clinically appropriate and life-changing.

What’s controversial isn’t the drug.

It’s how employers are deploying it.

In too many health plans, GLP-1s are being used as the metabolic strategy instead of as a tool inside one. And those are not the same thing.

In this episode, Dr. Andrew White breaks down why weight loss alone does not equal metabolic durability and why employers who ignore sequencing, movement capacity, and off-ramps may be increasing long-term pharmacy exposure instead of reducing risk.

If you’re a CFO, broker, HR leader, or operator evaluating GLP-1 coverage, this episode gives you a practical framework you can use in your next renewal meeting.

 ...